MarketPeel
Insider Trading Intelligence
Pricing
…
AH

Andrew Hirsch

CCCC
PRESIDENT & CEO · C4 THERAPEUTICS, INC. · CIK 0001586707
FILING MIX · LIFETIME57%/43%
BUYS
31
SELLS
23
TOTAL VALUE
$669.0K
COMPANIES
3
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
1,150,906
AVG SELL PX
$5.76
TRADE KIND
SHOWING 54 / 54
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Andrew Hirsch, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+7.65%+1.54%+6.11%+6.11%—
14d1+100.00%+1.60%-5.06%+6.66%+6.66%—
30d1+0.00%-23.06%-10.48%-12.57%-12.57%—
60d1+0.00%-31.85%-11.06%-20.79%-20.79%—
90d1+100.00%+8.33%-11.96%+20.29%+20.29%—
180d1+0.00%-11.76%-17.16%+5.41%+5.41%—
1y1+0.00%-64.38%-5.32%-59.06%-59.06%—
2y1+0.00%-11.07%+21.93%-33.01%-33.01%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CCCC · 1,074,934 shares · as of Feb 15, 2026
0422,918845,8361,268,7541,691,672202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 31 buys / 23 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
51,700——51,700Jun 17, 2026Jun 22, 2026 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
President & CEO
20,400——1,083,991Feb 15, 2026Feb 18, 2026 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
9,057$1.89$17.1K1,074,934Feb 15, 2026Feb 18, 2026 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
39,154$1.89$74.0K1,083,991Feb 14, 2026Feb 18, 2026 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
President & CEO
81,725——1,123,145Feb 14, 2026Feb 18, 2026 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
700,000——1,123,145Feb 13, 2026Feb 18, 2026 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
37,500——37,500Jun 6, 2025Jun 10, 2025 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
9,370$3.18$29.8K423,145Feb 15, 2025Feb 18, 2025 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
335,300——335,300Feb 14, 2025Feb 18, 2025 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
223,500——445,362Feb 14, 2025Feb 18, 2025 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
12,847$3.18$40.9K432,515Feb 14, 2025Feb 18, 2025 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
President & CEO
12,500——227,412Nov 7, 2024Nov 12, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
5,550$6.04$33.5K221,862Nov 7, 2024Nov 12, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
12,500——35,000Nov 7, 2024Nov 12, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
7,500——47,500Sep 16, 2024Sep 17, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
3,329$6.36$21.2K214,912Sep 16, 2024Sep 17, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
President & CEO
7,500——218,241Sep 16, 2024Sep 17, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
25,000——25,000May 30, 2024Jun 3, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
6,560$7.90$51.8K210,741Feb 15, 2024Feb 15, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
103,400——217,301Feb 14, 2024Feb 15, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
465,500——465,500Feb 14, 2024Feb 15, 2024 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
489,600——489,600Sep 18, 2023Sep 19, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
2,205$2.93$6.5K113,901Aug 30, 2023Aug 31, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
President & CEO
7,500——116,106Aug 30, 2023Aug 31, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
7,500——55,000Aug 30, 2023Aug 31, 2023 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Jun 1, 2023Jun 5, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
81,600——108,606Feb 15, 2023Feb 15, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
367,200——367,200Feb 15, 2023Feb 15, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
12,500——62,500Jan 30, 2023Feb 1, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
President & CEO
12,500——31,325Jan 30, 2023Feb 1, 2023 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
4,319$7.78$33.6K27,006Jan 30, 2023Feb 1, 2023 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Jun 9, 2022Jun 13, 2022 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
3,675$7.01$25.8K18,825May 26, 2022Jun 14, 2022 ↗View →
CCCC
C4 THERAPEUTICS, INC.
SALE
President & CEO
12,500——75,000May 25, 2022May 27, 2022 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
President & CEO
12,500——22,500May 25, 2022May 27, 2022 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASE
President & CEO
10,000$8.40$84.0K10,000Apr 12, 2022Apr 12, 2022 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
87,500——87,500Feb 23, 2022Feb 23, 2022 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
11,538——11,538Jun 3, 2021Jun 4, 2021 ↗View →
CCCC
C4 THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,691,672——1,691,672Oct 1, 2020Oct 5, 2020 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
11,538——11,538Jun 10, 2020Jun 12, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
5,893——26,199Apr 22, 2020Apr 24, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
5,893——11,785Apr 22, 2020Apr 24, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,927$45.91$88.5K24,272Apr 22, 2020Apr 24, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,599$40.64$65.0K20,306Apr 14, 2020Apr 15, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
5,387——21,905Apr 13, 2020Apr 15, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
5,387——10,775Apr 13, 2020Apr 15, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
1,056$48.66$51.4K16,518Feb 24, 2020Feb 25, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
3,333——6,667Feb 22, 2020Feb 25, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
3,333——17,574Feb 22, 2020Feb 25, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
886$52.01$46.1K14,241Feb 18, 2020Feb 19, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
2,750——15,127Feb 16, 2020Feb 19, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,750——2,750Feb 16, 2020Feb 19, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,000——12,000Feb 14, 2020Feb 19, 2020 ↗View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Feb 14, 2020Feb 19, 2020 ↗View →
Other insiders · CCCC
Loading peer insiders…
About this filer
CIK 0001586707
ROLE
President & CEO
PRIMARY
CCCC
COMPANIES
3
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001586707DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback